England's Pricing Negotiations Collapse Over AstraZeneca and Daiichi Sankyo's Breast Cancer Drug

In a significant setback for cancer patients in England, negotiations regarding the pricing of a potentially life-saving breast cancer drug, developed by AstraZeneca and Daiichi Sankyo, have fallen apart. This development leaves many women in need of the medication in a precarious position as they grapple with limited treatment options.

Continue reading